We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Agilent Technologies | NYSE:A | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.66 | 0.43% | 154.74 | 154.84 | 152.50 | 152.57 | 418,975 | 17:59:27 |
From May 2022 to May 2024
By Will Feuer
Agilent Technologies Inc. said the Food and Drug Administration has approved Teva Pharmaceutical Industries Ltd.'s content uniformity method using Agilent's TRS100 Raman quantitative pharmaceutical analysis system.
Agilent said its TRS100 system helps measure how much active pharmaceutical ingredient is inside a tablet or capsule, and whether the amount is uniform across a batch.
"It is a substantial investment to change manufacturing and QC processes, and an FDA approval minimizes the perceived risk of adopting this new technology," said Geoff Winkett, Agilent vice president of molecular spectroscopy.
The FDA's approval of the TRS100 method for content uniformity testing by Teva is a key milestone for the product, Mr. Winkett said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
July 05, 2022 08:41 ET (12:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Agilent Technologies Chart |
1 Month Agilent Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
